宫颈阴道镜检查:适应证与风险评估
本文综述阴道镜检查在评估阴道、外阴及宫颈病变中的适应证演变,强调结合患者高危宫颈上皮内瘤变(CIN)和癌症风险因素进行分层。文章指出初级保健医生应提供HPV疫苗接种、识别细胞学与HPV亚型及持续感染带来的风险等级,并熟悉2019年ASCCP指南以建立异常结果随访系统。
要点
- 初级保健医生应为9至26岁患者提供HPV疫苗接种,并开展宫颈癌筛查与随访指导。
- 应识别细胞学、HPV亚型及HPV感染持续状态所提示的高级别CIN和癌症风险等级。
- 对宫颈癌最高风险患者及特定条件患者应开展共享决策,讨论即刻LEEP与多点活检加颈管取样的选择。
核心结论
- 阴道镜检查实践已演变为结合患者高级别CIN和癌症风险因素进行评估。
- 初级保健医生需熟悉2019年ASCCP指南并建立异常细胞学、高危HPV阳性、确诊CIN及宫颈癌的随访系统。
- 有异常宫颈癌筛查史的患者需要监测,不同于既往筛查正常者的常规筛查。
研究设计与样本
- 本文为综述,汇总宫颈癌筛查与指南变化、HPV疫苗接种建议及ASCCP阴道镜标准对初级保健医生的影响。
主要发现
- 细胞学、HPV亚型及HPV感染持续状态可提示高级别CIN和癌症的不同风险程度。
- 对宫颈癌最高风险患者以及25岁以上且至少具备HPV-16、HPV-18和高别鳞状上皮内病变细胞学中两项的患者,应共享决策选择即刻LEEP或多点活检加颈管取样。
- CIN 2或更严重病变患者建议长期监测。
关键数值与推荐
- 建议为9至26岁所有患者提供HPV疫苗接种。
- 对25岁以上且至少具备以下两项的患者(HPV-16、HPV-18、高别鳞状上皮内病变细胞学)应共享决策讨论即刻LEEP与阴道镜多点活检加颈管取样。
- CIN 2或更严重病变患者建议长期监测。
临床怎么用
- 初级保健医生应提供HPV疫苗接种、宫颈癌筛查及随访指导。
- 应处理可改变风险因素如烟草使用,并基于个体风险提供阴道镜检查咨询。
- 应熟悉2019年ASCCP指南并建立诊所系统确保异常结果适当随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The practice of colposcopy, a diagnostic procedure to evaluate for vaginal, vulvar, and cervical dysplasia, has evolved to incorporate patient risk factors for high-grade cervical intraepithelial neoplasia (CIN) and cancer. Changes in cervical cancer screening and guidelines, human papillomavirus (HPV) vaccination recommendations, and colposcopy standards from the American Society for Colposcopy and Cervical Pathology (ASCCP) have implications for all primary care clinicians, not only those who perform colposcopies. Primary care clinicians should offer HPV vaccination to all patients between the ages of nine and 26, in addition to cervical cancer screening and follow-up guidance. Primary care clinicians should recognize the degrees of risk of high-grade CIN and cancer conferred by cytology, HPV subtype, and persistence of HPV infection. Clinicians should address modifiable risk factors such as tobacco use, and provide counseling to patients about colposcopy based on their individual risks. Clinicians should conduct shared decision-making about immediate loop electrosurgical excision procedure vs. colposcopy with multiple biopsies and endocervical sampling for patients with the highest risk of cervical cancer, and for patients who are older than 25 years with at least two of the following: HPV-16, HPV-18, and high-grade squamous intraepithelial lesion cytology. Primary care clinicians should be familiar with the 2019 ASCCP guidelines and develop clinic-based systems to ensure appropriate follow-up of abnormal cytology, positive high-risk HPV testing, diagnosed CIN, and cervical cancer. Patients with an abnormal cervical cancer screening history require surveillance, which differs from routine screening for patients with normal prior screening results. Long-term surveillance is recommended for patients with CIN 2 or worse.
引用
- Burness JV, Schroeder JM, Warren JB, et al. Cervical Colposcopy: Indications and Risk Assessment. Am Fam Physician. 2020. PMID: 32603071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。